D
David A. Gewirtz
Researcher at Virginia Commonwealth University
Publications - 182
Citations - 22854
David A. Gewirtz is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Autophagy & Cancer. The author has an hindex of 47, co-authored 162 publications receiving 18755 citations. Previous affiliations of David A. Gewirtz include VCU Medical Center.
Papers
More filters
Journal ArticleDOI
Disentangling the Mechanisms of Radiation-Induced Heart Disease in the Treatment of Breast Cancer
Eleonora Mezzaroma,Elisabeth Weiss,Ross B. Mikkelsen,David A. Gewirtz,Justin M. Canada,Egidio Del Fabbro,Stefano Toldo,Antonio Abbate +7 more
TL;DR: This poster presents a probabilistic procedure to characterize the immune response of the central nervous system to treat central giant cell granuloma.
Journal ArticleDOI
Anibamine, a Natural Product CCR5 Antagonist, as a Novel Lead for the Development of Antiprostate Cancer Agents.
Xueping Zhang,Kendra M. Haney,Amanda C. Richardson,Eden N. Wilson,David A. Gewirtz,Joy L. Ware,Zendra E. Zehner,Yan Zhang +7 more
TL;DR: It is demonstrated that anibamine (I), a recently isolated alkaloid from Aniba species, produces significant inhibition of prostate cancer cell proliferation at micromolar to submicromolar concentrations as well as suppressing adhesion and invasion of the highly metastatic M12 prostate cancercell line.
Journal ArticleDOI
Loss of sphingosine kinase 2 protects against cisplatin induced-kidney injury.
Dengpiao Li Xie,Gaizun Hu,Chaoling Chen,Fereshteh Ahmadinejad,Weili Wang,Pin-Lan Li,David A. Gewirtz,Ningjun Li +7 more
TL;DR: In conclusion, SphK2 may be used as a potential therapeutic target for the prevention or treatment of cisplatin-induced kidney injury and inhibition of Sphk2 protects against cisPlatin- induced kidney injury.
Journal Article
Abstract 14774: Preserved Left Ventricular Contractile Reserve After Thoracic Irradiation in the Interleukin-1 Receptor Knock Out Mouse
Eleonora Mezzaroma,Stefano Toldo,Benjamin W. Van Tassell,Carlo Marchetti,Ross B. Mikkelsen,David A. Gewirtz,Antonio Abbate +6 more
TL;DR: It is proposed to assess the role of IL-1 on the long-term effects of XRT-induced cardiomyopathy and the use of beta-adrenergic receptor agonist, 10 ng/mouse, was used to measure the contractile reserve.
Journal ArticleDOI
The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer.
Adam T. Nelczyk,Liqian Ma,Anasuya Gupta,Hashni E. Gamage,Michael T. McHenry,Madeline A. Henn,Mohammed Kadiri,Yu Wang,Natalia Krawczynska,Shruti Bendre,Sisi He,Sayyed Hamed Shahoei,Zeynep Madak-Erdogan,Shih-Hsuan Hsiao,Tareq Saleh,Valerie J. Carpenter,David A. Gewirtz,Michael J. Spinella,Erik R. Nelson +18 more
TL;DR: In this article , the authors found that TLX (NR2E1) expression was associated with prolonged recurrence-free survival and overall survival for breast cancer patients with either ERα-negative or basal-like tumors.